Literature DB >> 10647067

Effects of endothelin-1 and nitric oxide on glucokinase activity in isolated rat hepatocytes.

L D Monti1, G Valsecchi, S Costa, E P Sandoli, C V Phan, A E Pontiroli, G Pozza, P M Piatti.   

Abstract

To test the hypothesis that endothelin-1 (ET-1) and nitric oxide (NO) influence glucokinase (GK) activity in an opposite manner, we evaluated the effects of ET-1, L-NAME, an inhibitor of NO synthase, and L-arginine, a substrate for NO synthase, on GK activity and glycogen content in isolated rat hepatocytes. Moreover, to understand the receptor involved in the process, the effects of BQ 788, a specific antagonist of ETB receptor, and PD 142893, an antagonist of ETA-ETB receptors, were also evaluated. GK activity, cyclic guanosine monophosphate (cGMP), and glycogen intracellular content were measured on isolated hepatocytes, while glucose levels and NO as NO2-/NO3- were determined in the medium. High ET-1 levels induced a 20% decrease of NO2-/NO3- levels and cGMP intracellular content, followed by a 49% reduction of GK activity and a 15% decrease of glycogen. In parallel, a 10% increase of glucose in the medium was observed. In the presence of L-NAME, GK activity and glycogen levels showed analogous decrements as observed with ET-1. Also in this case, a significant decrease of the intracellular content of cGMP was observed. No synergistic effects of ET-1 and L-NAME were observed. L-Arginine was able to counteract the inhibitory effect of ET-1 on cGMP and GK activity. Glycogen content was slightly but not significantly reduced, and under those conditions, a significant decrease of glucose in the medium was observed. When hepatocytes were incubated with ET-1 plus BQ 788 or ET-1 plus PD 142893, GK activity was unchanged. Interestingly, no changes were observed in NO2-/NO3- levels and the intracellular content of cGMP was not modified when the antagonists of ET-1 receptors were added to the medium. In conclusion, the present study shows that the NO pathway seems to be an important regulator of GK activity and glycogen content through cGMP activity. In addition, ET-1 seems to be not active per se, but its activity seems mediated by a simultaneous decrease of NO levels.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10647067     DOI: 10.1016/s0026-0495(00)90763-7

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  3 in total

1.  Supplementation with L-arginine favorably influences plasminogen activator inhibitor type 1 concentration in obese patients. A randomized, double blind trial.

Authors:  P Bogdanski; M Szulinska; J Suliburska; D Pupek-Musialik; A Jablecka; H Witmanowski
Journal:  J Endocrinol Invest       Date:  2012-06-25       Impact factor: 4.256

2.  In silico models for dynamic connected cell cultures mimicking hepatocyte-endothelial cell-adipocyte interaction circle.

Authors:  Chiara Andreoni; Gianni Orsi; Carmelo De Maria; Francesca Montemurro; Giovanni Vozzi
Journal:  PLoS One       Date:  2014-12-15       Impact factor: 3.240

3.  Changes in mineral status are associated with improvements in insulin sensitivity in obese patients following L-arginine supplementation.

Authors:  Joanna Suliburska; Paweł Bogdanski; Monika Szulinska; Danuta Pupek-Musialik; Anna Jablecka
Journal:  Eur J Nutr       Date:  2013-05-25       Impact factor: 5.614

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.